COMPANY

Progenra Inc.

HQ: Malvern, PA source · progenra.com ↗ · Mid-Atlantic

Location: Malvern, PA · source · Oct 15, 2026

Profile checked Oct 10, 2026

50NIH grants

Timeline

May 16, 2025 Grant Government grant — SBIR: $302,421 (annual award, as published), announced May 16, 2025. Agency: NIH/NIAID. Source: government award database. source ↗

Funding

Last 2 years.

May 16, 2025 Government grant — SBIR: $302,421 (annual award, as published), announced May 16, 2025. Agency: NIH/NIAID. Source: government award database. source ↗

NIH awards 50

Annual award amounts. Total $23.7M.

Sep 19, 2024 NIH award 1R43DK138712-01 FY2024: $269,622 awarded for that fiscal year; activity R43 (SBIR); PI SURESH, KUMAR; recipient as written: PROGENRA, INC., MALVERN, PA. Ubiquitin pathway modulators for treating pancreatiti source ↗
Sep 1, 2022 NIH award 1R43AR081153-01A1 FY2022: $254,561 awarded for that fiscal year; activity R43 (SBIR); PI SURESH, KUMAR; recipient as written: PROGENRA, INC., MALVERN, PA. Development of ITCH-activating IRAK4 degraders as d source ↗
Mar 30, 2022 NIH award 1R43HL162163-01 FY2022: $296,932 awarded for that fiscal year; activity R43 (SBIR); PI SURESH, KUMAR; recipient as written: PROGENRA, INC., MALVERN, PA. Parkin activators for cardioprotective therapies source ↗
Sep 5, 2021 NIH award 1R43DK127851-01A1 FY2021: $265,978 awarded for that fiscal year; activity R43 (SBIR); PI STERNER, DAVID E; recipient as written: PROGENRA, INC., MALVERN, PA. Novel TXNIP degraders for treating diabetes source ↗
Jul 9, 2020 NIH award 1R43GM139493-01 FY2020: $297,442 awarded for that fiscal year; activity R43 (SBIR); PI SURESH, KUMAR; recipient as written: PROGENRA, INC., MALVERN, PA. Targeted protein stabilization using Protein Rescue T source ↗
Sep 10, 2019 NIH award 1R43DK120250-01A1 FY2019: $224,618 awarded for that fiscal year; activity R43 (SBIR); PI STERNER, DAVID E; recipient as written: PROGENRA, INC., MALVERN, PA. Nonalcoholic Steatohepatitis Therapies from the source ↗
Aug 30, 2019 NIH award 1R43AR074799-01A1 FY2019: $224,461 awarded for that fiscal year; activity R43 (SBIR); PI SURESH, KUMAR; recipient as written: PROGENRA, INC., MALVERN, PA. Ubiquitin E3 ligase activators for treatment of pso source ↗
May 18, 2018 NIH award 5R44AG053092-03 FY2018: $643,048 awarded for that fiscal year; activity R44 (SBIR); PI SURESH, KUMAR; recipient as written: PROGENRA, INC., MALVERN, PA. Small molecule Parkin activators to treat Alzheimer's source ↗
Apr 27, 2018 NIH award 1R43AI138753-01 FY2018: $223,362 awarded for that fiscal year; activity R43 (SBIR); PI SURESH, KUMAR; recipient as written: PROGENRA, INC., MALVERN, PA. Small-molecule inhibition of mechanisms shared across source ↗
Dec 22, 2017 NIH award 5R44AI109980-03 FY2018: $636,155 awarded for that fiscal year; activity R44 (SBIR); PI SURESH, KUMAR; recipient as written: PROGENRA, INC., MALVERN, PA. Ubiquitin pathway inhibitors for treatment of asthma source ↗
Aug 29, 2017 NIH award 1R43CA213582-01A1 FY2017: $224,995 awarded for that fiscal year; activity R43 (SBIR); PI SURESH, KUMAR; recipient as written: PROGENRA, INC., MALVERN, PA. Small molecule ubiquitin ligase modulators for immu source ↗
Aug 25, 2017 NIH award 2R44AG053092-02 FY2017: $741,032 awarded for that fiscal year; activity R44 (SBIR); PI WANG, FENG; recipient as written: PROGENRA, INC., MALVERN, PA. Small molecule Parkin activators to treat Alzheimer's Di source ↗
Jan 26, 2017 NIH award 5R44CA174037-03 FY2017: $748,944 awarded for that fiscal year; activity R44 (SBIR); PI WEINSTOCK, JOSEPH; recipient as written: PROGENRA, INC., MALVERN, PA. Chemical Optimization of a novel class of USP7 in source ↗
Jan 10, 2017 NIH award 2R44AI109980-02A1 FY2017: $757,044 awarded for that fiscal year; activity R44 (SBIR); PI SURESH, KUMAR; recipient as written: PROGENRA, INC., MALVERN, PA. Ubiquitin pathway inhibitors for treatment of asthm source ↗
Sep 2, 2016 NIH award 1R41HL130207-01 FY2016: $339,094 awarded for that fiscal year; activity R41 (STTR); PI ROWE, STEVEN MARK; recipient as written: PROGENRA, INC., MALVERN, PA. In vitro human model for individualized response source ↗
Jul 21, 2016 NIH award 1R43HL134411-01 FY2016: $204,995 awarded for that fiscal year; activity R43 (SBIR); PI STERNER, DAVID E; recipient as written: PROGENRA, INC., MALVERN, PA. A novel mechanism based therapy for cystic fibrosi source ↗
Jul 5, 2016 NIH award 1R43AI126950-01 FY2016: $205,893 awarded for that fiscal year; activity R43 (SBIR); PI SURESH, KUMAR; recipient as written: PROGENRA, INC., MALVERN, PA. Novel ubiquitin protease inhibitor for treating asthm source ↗
Apr 22, 2016 NIH award 1R43AG053092-01 FY2016: $224,681 awarded for that fiscal year; activity R43 (SBIR); PI WANG, FENG; recipient as written: PROGENRA, INC., MALVERN, PA. Small molecule Parkin activators to treat Alzheimer's Di source ↗
Feb 2, 2016 NIH award 2R44CA174037-02 FY2016: $748,944 awarded for that fiscal year; activity R44 (SBIR); PI WEINSTOCK, JOSEPH; recipient as written: PROGENRA, INC., MALVERN, PA. Chemical Optimization of a novel class of USP7 in source ↗
Sep 17, 2015 NIH award 1R43AG052242-01 FY2015: $205,197 awarded for that fiscal year; activity R43 (SBIR); PI WANG, FENG; recipient as written: PROGENRA, INC., MALVERN, PA. Mitophagy inhibitors for treatment of Alzheimer's Diseas source ↗
Aug 6, 2015 NIH award 5R44ES025600-03 FY2015: $611,663 awarded for that fiscal year; activity R44 (SBIR); PI STERNER, DAVID E; recipient as written: PROGENRA, INC., MALVERN, PA. Selective inhibitors of ubiquitin E3 ligase to tre source ↗
Jul 20, 2015 NIH award 5R44HL114299-03 FY2015: $667,073 awarded for that fiscal year; activity R44 (SBIR); PI STERNER, DAVID E; recipient as written: PROGENRA, INC., MALVERN, PA. Novel molecular therapeutics for cystic fibrosis source ↗
Jun 9, 2015 NIH award 1R43AG049535-01A1 FY2015: $224,804 awarded for that fiscal year; activity R43 (SBIR); PI SURESH, KUMAR; recipient as written: PROGENRA, INC., MALVERN, PA. Novel E3 ligase inhibitors for treatment of neurode source ↗
Apr 22, 2015 NIH award 5R44GM097827-03 FY2015: $611,190 awarded for that fiscal year; activity R44 (SBIR); PI STERNER, DAVID E; recipient as written: PROGENRA, INC., MALVERN, PA. Ubiquitin E3 ligase detection by fluorescence reso source ↗
Apr 6, 2015 NIH award 1R43DK104482-01 FY2015: $222,938 awarded for that fiscal year; activity R43 (SBIR); PI MATTERN, MICHAEL R; recipient as written: PROGENRA, INC., MALVERN, PA. Development of novel drugs to treat obesity source ↗
Sep 22, 2014 NIH award 9R44ES025600-02A1 FY2014: $611,663 awarded for that fiscal year; activity R44 (SBIR); PI STERNER, DAVID E; recipient as written: PROGENRA, INC., MALVERN, PA. Selective inhibitors of ubiquitin E3 ligase to t source ↗
Jul 25, 2014 NIH award 1R43CA174037-01A1 FY2014: $224,974 awarded for that fiscal year; activity R43 (SBIR); PI WEINSTOCK, JOSEPH; recipient as written: PROGENRA, INC., MALVERN, PA. Chemical optimization of a novel class of USP7 source ↗
Jul 22, 2014 NIH award 2R44HL114299-02 FY2014: $668,380 awarded for that fiscal year; activity R44 (SBIR); PI STERNER, DAVID E; recipient as written: PROGENRA, INC., MALVERN, PA. Novel molecular therapeutics for cystic fibrosis source ↗
Jul 9, 2014 NIH award 1R43NS087686-01 FY2014: $224,512 awarded for that fiscal year; activity R43 (SBIR); PI NICHOLSON, BENJAMIN; recipient as written: PROGENRA, INC., MALVERN, PA. Novel treatment for Huntington???s Disease source ↗
Jul 7, 2014 NIH award 1R43CA180173-01A1 FY2014: $224,768 awarded for that fiscal year; activity R43 (SBIR); PI STERNER, DAVID E; recipient as written: PROGENRA, INC., MALVERN, PA. Ubiquitin based therapy of aggressive cancer cel source ↗